Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study


PILANCI K. N., Saglam S., Okyar A., YÜCEL S., Pala-Kara Z., Ordu C., ...More

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.78, no.1, pp.143-150, 2016 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 78 Issue: 1
  • Publication Date: 2016
  • Doi Number: 10.1007/s00280-016-3067-x
  • Journal Name: CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.143-150
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No

Abstract

The aim of this study was to evaluate safety and toxicity of chronomodulated capecitabine administered in the morning and at noon according to a specific time schedule (Brunch Regimen: Breakfast and Lunch) as a part of first-line XELOX chemotherapy in patients with metastatic colorectal cancer.